Original article
English
Henry ML, Pelletier RP, Elkhammas EA, Bumgardner GL, Davies EA, Ferguson RM.
Department of Surgery, Division of Transplantation, College of Medicine, The Ohio State University, 16454 Upham Drive, Columbus, OH 43210, USA. henry.6@osu.edu
Clin Transplant. 2001 Dec;15(6):410-4.
Abstract
Recent improvements in immunosuppression and subsequent decreases in the incidence of acute rejection have brought into question the benefit of the use peri-transplant antibody therapy (i.e. induction therapy). In the current era of immunosuppression that includes mycophenolate mofetil (MMF) and cyclosporine emulsion (Neoral, Novartis, Basle, Switzerland), we designed and have completed a prospective, randomized trial to address this question. Cadaveric and living donor renal allograft recipients were randomized to receive either OKT3/MMF/delayed Neoral/prednisone or MMF/immediate Neoral/prednisone without OKT3. The incidence of rejection episodes was the primary end point. Patients with delayed graft function were excluded. All rejection episodes were biopsy proven and all patients have been followed for a minimum of 2 yr. Fifty-four patients received OKT3 induction, of which 6 patients suffered a rejection episode (11%), while 13 patients (27%) not receiving OKT3 (p=0.04) had a rejection episode. Four patients in the no OKT3 group suffered multiple rejections, while there were only 2 with more than one episode in the OKT3 group. There was no increased incidence of infectious complications in the group receiving OKT3. Hospital costs tended to be higher in the OKT3-treated group, but were not significantly different. The low incidence of rejection in the OKT3-treated group was intriguing and validates the use of antibody therapy in the early post-operative periods even in the era of improved baseline immunosuppression.
Keywords: A randomized prospective trial of OKT3 induction in the current immunosuppression era.
Link/DOI: http://www.blackwell-synergy.com/doi/abs/10.1034/j.1399-0012.2001.150608.x